DARIOHEALTH CORP.

DRIO

CIK 0001533998 · Quarterly mode · latest period FY2025 (Q4) (ending 2025-12-31) · sourced from SEC EDGAR

At a glance · FY2025 (Q4)

Revenue
$5M
↓-31.2% -$2Mvs FY2024 (Q4)
Operating Income
$110K
Gross Profit
$3M
↓-33.3% -$1Mvs FY2024 (Q4)

Quality Score

Quality score

6-dimension fundamental snapshot · latest annual filed values · S&P 500 calibration

Average
46/100
  • Profitability
    0ROIC -29.8% (10% = solid, 20%+ = moat)
  • Liquidity
    100Current Ratio 3.76 (above 1.5 = solid)
  • Leverage
    77D/E 0.45 (under 0.5 = conservative)
  • Efficiency
    0Asset Turnover 0.20x (1.0+ = capital-efficient)
  • Growth
    0Revenue YoY -31.2% (10% = solid, 25%+ = elite)
  • Margin Trend
    100Op Margin -189.4% · trend +77.0pts (4Q avg vs prior 4Q)

Calibrated to S&P 500 medians. Each sub-score is computed from a single CFA-grade ratio (Profitability = ROIC, Liquidity = Current Ratio, Leverage = D/E, Efficiency = Asset Turnover, Growth = Revenue YoY, Margin Trend = 4Q operating-margin avg vs prior 4Q). Overall = simple mean.

Capital allocation · trailing 4 quarters

how the company spent its cash
Capex (TTM)
$142K
investment in PP&E
Stock buybacks (TTM)
share count reduction
Stock-based comp (TTM)
non-cash dilution

Balance sheet · 2025-12-31

latest filed snapshot
Total assets
$110M
everything owned
Stockholders' equity
$68M
shareholder claim
Net debt
$9M
LT debt minus cash

Recent performance · 56 quarters

Revenue↓-31.2% -$2M
$5M
Net Income↑+15.1% +$2M
$-10M
Free Cash Flow↓-23.8% -$5K
$-26K
Operating Margin↓-27.4pts
-189.4%

Drill down